Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-03-21
2006-03-21
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S319000
Reexamination Certificate
active
07015229
ABSTRACT:
This invention relates to substituted pyrimidinone and pyrimidithione derivatives that bind with high affifnity to CRF1 receptors, including human CRF1 receptors. This invention also relates to methods of using the compounds of the invention to treat a disorder or condition, the treatment of which can be effected or facilitated by antagonizing a CRF receptor, such as CNS disorders or diseases, particularly anxiety disorders, and depression and stress related disorders.
REFERENCES:
patent: 6043260 (2000-03-01), Chen et al.
patent: 0826673 (1996-04-01), None
patent: 1097709 (2001-05-01), None
patent: WO 00/69832 (2000-11-01), None
patent: WO 01/68614 (2001-09-01), None
patent: WO 02/06242 (2002-01-01), None
Kehne et al., PubMed Abstract (Curr Drug Targets CNS Neurol Disord. 1(5):467-93) Oct. 2002.
Mitchell, PubMed Abstract (Neurosci Biobehav Rev. 22(5):635-51) Sep. 1998.
Suarez et al., PubMed Abstract (Medicina (B Aires) 59(4):385-92) 1999.
van Heeswijk et al., PubMed Abstract (Antivir Ther 6(4):201-29) Dec. 2001.
Damazio, Alzheimer's Disease and Related Dementias, Cecil Textbook of Medicine, vol. 2, pp. 1992-1996, 1996.
Layzer, Degenerative Diseases of the Nervous System, Cecil Textbook of Medicine, vol. 2, pp. 2050-2057, 1996.
Simone, Oncology: Introduction, Cecil Textbook of Medicine, vol. 1, pp. 1004-1010, 1996.
Arato M. et al., Biol. Psychiatry, 1989, 25:355.
Banki C.M. et al., Am. J. Psychiatry, 1987, 144:873.
Berridge, C. W. and A.J. Dunn, Regul. Peptides, 1986, 16:83.
Berridge, C. W. and A. J. Dunn, Horm. Behav., 1987, 21:393.
Berridge, C. W. and A. J. Dunn, Brain Research Reviews, 1990, 15:71.
Blalock, Physiological Reviews, 1989, 69:1.
Britton, K. T. , et al., Psychopharmacology, 1985, 86:170.
Britton, K. T. , Psychopharmacology, 1988, 94:306.
De Souze, E.B., Hosp. Practice, 1988, 23:59.
De Souza, E. B. et al., J. Neurosci., 1985, 5:3189.
France et al., Biol. Psychiatry, 1988, 28:86.
Gold, P. W. et al., Am. J. Psychiatry, 1984, 141:619.
Gold, P. W. et al., New Engl. J. Med., 1986, 314:1129.
Grigoriadis, et al., Neuropsychopharmacology, 1989, 2:53.
Holaboer F. et al., Psychoneuroendocrinology, 1984, 9:147.
Koob G. F., Persp. Behav. Med., 1985, 2:39.
Morley, J.E. et al., Life Sci., 1987, 41:527.
Nemeroff, et al., Science, 1984, 226:1342.
Nemeroff C.B., et al., Arch. Gen Psychiatry, 1988, 45:577.
Rivier J. et al., Proc. Natl. Acad. Sci (USA), 1983, 80:4851.
Sapolsky, R. M. , Arch. Gen. Psychiatry, 1989, 46:1047 (Abstract only).
Vale W. et al, Science, 1981, 213:1394.
Vale W. et al, Rec. Prog. Horm. Res., 1983, 39:245.
D. R. Britton, Intraventricular Corticotropin-Releasing Factor Enhances Behavioral Effects of Novelty, Life Sciences, Vo. 31, 1982, pp. 363-367, Pergamon Press, U. S. A.
Corbett Jeffrey W.
Ennis Michael Dalton
Frank Kristine E.
Fu Jian-Min
Hoffman Robert Louis
Appleman Jolene W.
Pfizer Inc
Rao Deepak
Zelson Steve T.
LandOfFree
Substituted pyrimidinones and pyrimidinthiones does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted pyrimidinones and pyrimidinthiones, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted pyrimidinones and pyrimidinthiones will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3544217